Physician profile

Toussaint Smith

Cardiovascular Disease · Sugar Land, TX

NPI 1902843949

$12,023.98

in general payments reported to CMS, 2019-2025

48 companies · $1,938 in 2025

The $1,938 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,670.81

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $1,152.78 2019-2024 Xarelto
Sanofi-Aventis U.S. LLC $1,136.44 2019-2024
Novartis Pharmaceuticals Corporation $1,110.17 2019-2025 Leqvio
Amgen INC. $986.72 2019-2025 Repatha, Repatha
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $799.61 2019-2025 Lifevest
Merck Sharp & Dohme LLC $773.24 2021-2025 Verquvo, Capvaxive
Astrazeneca Pharmaceuticals Lp $684.12 2019-2025 Farxiga, Wainua
Boston Scientific Corporation $567.77 2019-2025 Watchman Flx, Resonate El Icd Vr, Lux-Dx Insertable Cardiac Monitor
Pfizer INC. $520.74 2019-2025
E.R. Squibb & Sons, L.L.C. $517.87 2019-2025 Eliquis, Camzyos
Boehringer Ingelheim Pharmaceuticals, INC. $480.99 2021-2025 Jardiance
Medtronic, INC. $372.70 2021-2025 Corevalve Evolut R, Harmony
Irhythm Technologies, INC. $335.00 2023-2024 Zio Xt Patch, Zio Monitor
Impulse Dynamics (USA) INC. $281.03 2023-2024 Optimizer, Optimizer
Actelion Pharmaceuticals US, INC. $265.62 2019-2025 Opsumit, Uptravi
Show all 48 companies
CompanyGeneral paymentsYearsTop products
Abbott Laboratories $242.62 2019-2025 Cardiomems, Confirm Rx, Thoratec Heartmate 3 Lvas Implant Kit
Scpharmaceuticals INC. $158.03 2023-2025
Kiniksa Pharmaceuticals International, Plc $155.02 2024 Arcalyst
Heartflow, INC. $119.89 2019-2024
Novo Nordisk INC $112.67 2024-2025 Ozempic, Rybelsus
Esperion Therapeutics, INC. $104.37 2020-2025 Nexletol
Astellas Pharma US INC $92.04 2019-2020
Lexicon Pharmaceuticals, INC. $87.73 2023-2024 Inpefa
Amarin Pharma, INC. $85.09 2019-2021
Cardiva Medical, INC. $81.67 2022-2023 Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs
Alnylam Pharmaceuticals INC. $72.15 2023-2025 Onpattro
Angiodynamics, INC. $65.69 2019
Edwards Lifesciences Corporation $59.98 2022-2024 Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Arbor Pharmaceuticals, INC. $57.10 2019-2022
Cvrx, INC. $51.07 2023-2024 Barostim Neo System
Bayer Healthcare Pharmaceuticals INC. $48.89 2023
Glaxosmithkline, LLC. $47.48 2025 Shingrix, Arexvy
Kestra Medical Technology Services, INC. $43.92 2024-2025 Assure Wcd
Kowa Pharmaceuticals America, INC. $41.98 2019-2022
Cagent Vascular INC $38.09 2025 Serrantor
Azurity Pharmaceuticals, INC. $36.49 2024 Edarbi
American Regent $29.31 2023 Injectafer
Genzyme Corporation $29.16 2024
Althera Pharmaceuticals LLC $22.22 2021
Agepha Pharma Fz LLC $21.23 2024 Lodoco
Medtronic Vascular, INC. $20.87 2019
Ge Healthcare $19.34 2024
Kiniksa Pharmaceuticals, Ltd. $18.67 2023 Arcalyst
Infobionic, INC $17.20 2022
Inspire Medical Systems, INC. $17.06 2023 Inspire
Preventice Services, LLC $14.55 2021
Bardy Diagnostics, INC. $14.00 2022
Tactile Systems Technology INC $13.60 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Toussaint Smith

$12,023.98

in general payments reported 2019-2025

Years
2019-2025
Top company
Janssen Pharmaceuticals, INC
Context
The $1,938 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/41570/toussaint-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.